Pricing Availability Delivery Time Qty
Cat.No. 5480 - KRIBB11 | C13H12N6O2 | CAS No. 342639-96-7
Description: HSF1 inhibitor
Chemical Name: N2-1H-Indazol-5-yl-N6-methyl-3-nitro-2,6-pyridinediamine
Purity: ≥99% (HPLC)

Biological Activity

Heat shock factor (HSF) inhibitor (IC50 = 1.2 μM). Increases apoptosis in cancer cells treated with the HSP90 inhibitors Geldanamycin (Cat. No. 1368) and 17-AAG (Cat. No. 1515). Blocks downstream induction of HSP27 and HSP70. Inhibits tumor growth in vivo.

Technical Data

M. Wt 284.27
Formula C13H12N6O2
Storage Store at -20°C
Purity ≥99% (HPLC)
CAS Number 342639-96-7
PubChem ID 69894253
Smiles CNC1=NC(NC2=CC=C(NN=C3)C3=C2)=C([N+]([O-])=O)C=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 28.43 100

Preparing Stock Solutions

The following data is based on the product molecular weight 284.27. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.52 mL 17.59 mL 35.18 mL
5 mM 0.7 mL 3.52 mL 7.04 mL
10 mM 0.35 mL 1.76 mL 3.52 mL
50 mM 0.07 mL 0.35 mL 0.7 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets

Safety Datasheet


References are publications that support the products' biological activity.

Yoon et al (2011) KRIBB11 inhibits HSP70 synthesis through inhibition of heat shock factor 1 function by impairing the recruitment of positive transcription elongation factor b to the hsp70 promoter. J.Biol.Chem. 286 1737 PMID: 21078672

Samarasinghe et al (2014) Heat shock factor 1 confers resistance to Hsp90 inhibitors through p62/SQSTM1 expression and promotion of autophagic flux. Biochem. Pharmacol. 87 445 PMID: 24291777

If you know of a relevant reference for KRIBB11, please let us know.

Keywords: KRIBB11, supplier, HSF1, inhibitors, inhibits, heat, shock, factors, 1, HSP90, HSP70, HSP27, proteins, Hsp90, Hsp70, Other, Transcription, Factors, Hsp90, Tocris Bioscience

Citations for KRIBB11

Citations are publications that use Tocris products.

Currently there are no citations for KRIBB11. Do you know of a great paper that uses KRIBB11 from Tocris? If so please let us know.

KRIBB11 Reviews

Average Rating:

(Based on 0 Reviews)

1 Star
2 Star
3 Star
4 Star
5 Star

Have you used KRIBB11?

Submit a review and receive a $25US/€18/£15/$25CAN Amazon gift card if you include an image -$10US/€7/£6/$10CAN Amazon gift card for reviews without an image. Limited to verified customers in USA, Canada and Europe.

Literature in this Area


Cancer Research Product Guide

A collection of over 750 products for cancer research, the guide includes research tools for the study of:

  • Cancer Metabolism
  • Epigenetics in Cancer
  • Receptor Signaling
  • Cell Cycle and DNA Damage Repair
  • Angiogenesis
  • Invasion and Metastasis

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.